<SEC-DOCUMENT>0001193125-25-077980.txt : 20250410
<SEC-HEADER>0001193125-25-077980.hdr.sgml : 20250410
<ACCEPTANCE-DATETIME>20250410161715
ACCESSION NUMBER:		0001193125-25-077980
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250410
DATE AS OF CHANGE:		20250410

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Royalty Pharma plc
		CENTRAL INDEX KEY:			0001802768
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39329
		FILM NUMBER:		25828614

	BUSINESS ADDRESS:	
		STREET 1:		110 EAST 59TH STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
		BUSINESS PHONE:		(212) 883-0200

	MAIL ADDRESS:	
		STREET 1:		110 EAST 59TH STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>d943352ddefa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML><HEAD>
<TITLE>DEFA14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">8-K</FONT> </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 OR 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of The Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): April&nbsp;7, 2025 </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Royalty Pharma plc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in its Charter) </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>England and Wales</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-39329</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">98-1535773</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(State or other jurisdiction<BR>of incorporation)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Commission<BR>File Number)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(I.R.S.<BR>Identification No.)</B></TD></TR>
</TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="35%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>110 East 59<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Street</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>New York, New York</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#8194;&#8201;10022</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (212)
<FONT STYLE="white-space:nowrap">883-0200</FONT> </B></P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or former address, if changed since last report) </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&nbsp;12(b) of the Act: </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Trading<BR>symbol(s)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of each exchange<BR>on which registered</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Class&nbsp;A Ordinary Shares, par value $0.0001 per share</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">RPRX</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">The Nasdaq Stock Market LLC</TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#8194;&#9744; </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&#8194;&#9744;
</P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%" VALIGN="top" ALIGN="left"><B>Item&#8201;5.02.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective April&nbsp;7, 2025, Dr.&nbsp;Vlad Coric was appointed to
serve as a new member of the Board of Directors (the &#147;Board&#148;) of Royalty Pharma plc (the &#147;Company&#148;). Dr.&nbsp;Coric will stand for election for the first time at the Company&#146;s 2025 Annual General Meeting and Special Meeting
of Shareholders (&#147;Annual Meeting&#148;). If elected to serve on our Board, Dr. Coric is expected to become a member of the Management Development and Compensation Committee after the Annual Meeting. The Board has determined that Dr.&nbsp;Coric
meets the independence standards adopted by the Board in compliance with the Nasdaq Global Select Market corporate governance listing standards and Item&nbsp;407(a)&nbsp;of&nbsp;Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Coric does not have any family relationships with any of the executive officers or directors of the Company. There are no
arrangements or understandings between Dr.&nbsp;Coric and any other person pursuant to which he was appointed as a director of the Company. In&nbsp;connection with his appointment, Dr.&nbsp;Coric will enter into a standard deed of indemnity in the
form previously approved by the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Coric will receive compensation pursuant to the Company&#146;s Independent Director
Compensation Policy, as described in the Company&#146;s Preliminary Proxy Statement filed on February&nbsp;13, 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;8,
2025, the Company issued a press release announcing the appointment of Dr.&nbsp;Coric to the Board, which is attached as Exhibit 99.1 and incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%" VALIGN="top" ALIGN="left"><B>Item&#8201;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Exhibits. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Description</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release dated April&nbsp;8, 2025</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>104</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Note Regarding Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as
of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any
time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof. This document contains statements that constitute &#147;forward-looking
statements&#148; as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company&#146;s opinions, expectations, beliefs, plans, objectives, assumptions or projections
regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of Royalty Pharma&#146;s strategies, financing plans, growth opportunities, market growth, and plans for capital
deployment, plus the benefits of the Transaction (as defined in the Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on January&nbsp;10, 2025), including cash savings, enhanced alignment with shareholders,
increased investment returns, expectations regarding management continuity, transparency and governance, and the benefits of simplification to its structure. In some cases, you can identify such forward-looking statements by terminology such as
&#147;may,&#148; &#147;might,&#148; &#147;will,&#148; &#147;should,&#148; &#147;expects,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;target,&#148; &#147;forecast,&#148; &#147;guidance,&#148;
&#147;goal,&#148; &#147;predicts,&#148; &#147;project,&#148; &#147;potential&#148; or &#147;continue,&#148; the negative of these terms or similar expressions. Forward-looking statements are based on management&#146;s current beliefs and assumptions
and on information currently available to the company. However, these forward-looking statements are not a guarantee of Royalty Pharma&#146;s performance, and you should not place undue reliance on such statements, including because the Transaction
is subject to shareholder approval. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, and other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are
cautioned not to place undue reliance on such statements. Many of these risks are outside of Royalty Pharma&#146;s control and could cause its actual </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
results to differ materially from those it thought would occur. The forward-looking statements included in this document are made only as of the date hereof. Royalty Pharma does not undertake,
and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law. For further information, please
reference Royalty Pharma&#146;s reports and documents filed with the U.S. Securities and Exchange Commission (&#147;SEC&#148;) by visiting EDGAR on the SEC&#146;s website at www.sec.gov. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Information and Where to Find It </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
connection with the Transaction, Royalty Pharma will file with the SEC a proxy statement on Schedule 14A. The definitive proxy statement will be sent to the shareholders of Royalty Pharma seeking their approval of the Transaction and other related
matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT ON SCHEDULE 14A WHEN IT BECOMES AVAILABLE, AS WELL AS ANY OTHER RELEVANT
DOCUMENTS FILED WITH THE SEC IN CONNECTION WITH THE TRANSACTION OR INCORPORATED BY REFERENCE INTO THE PROXY STATEMENT, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION REGARDING ROYALTY PHARMA, THE TRANSACTION AND RELATED MATTERS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors and security holders may obtain free copies of these documents, including the proxy statement, and other documents filed with the SEC by the Company
through the website maintained by the SEC at <FONT STYLE="white-space:nowrap">https://www.sec.gov/cgi-bin/browse-edgar?CIK=1802768&amp;owner=exclude.</FONT> Copies of documents filed with the SEC by Royalty Pharma will be made available free of
charge by accessing its website at https://www.royaltypharma.com/investors/ or by contacting Royalty Pharma via email by sending a message to ir@royaltypharma.com. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Participants in the Solicitation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Royalty Pharma and its
directors and executive officers may be deemed to be participants in the solicitation of proxies from the shareholders of Royalty Pharma in connection with the Transaction under the rules of the SEC. Information about the interests of the directors
and executive officers of Royalty Pharma and other persons who may be deemed to be participants in the solicitation of shareholders of Royalty Pharma in connection with the Transaction and a description of their direct and indirect interests, by
security holdings or otherwise, will be included in the proxy statement related to the Transaction, which will be filed with the SEC. Information about the directors and executive officers of Royalty Pharma and their ownership of Royalty Pharma
ordinary shares is also set forth in Royalty Pharma&#146;s definitive proxy statement in connection with its 2024 Annual General Meeting of Shareholders, as filed with the SEC on April&nbsp;25, 2024 (and which is available at
https://www.sec.gov/ix?doc=/Archives/edgar/data/1802768/000114036124022029/ny20020881x1_def14a.htm) and in Royalty Pharma&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2024 (and
which is available at https://www.sec.gov/ix?doc=/Archives/edgar/data/0001802768/000180276825000010/rprx-20241231.htm). Information about the directors and executive officers of Royalty Pharma, their ownership of the Royalty Pharma ordinary shares,
and Royalty Pharma&#146;s transactions with related persons is set forth in the sections entitled &#147;Directors, Executive Officers and Corporate Governance,&#148; &#147;Security Ownership of Certain Beneficial Owners,&#148; and &#147;Certain
Relationships and Related Party Transactions&#148; included in Royalty Pharma&#146;s annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2024, which was filed with the SEC on
February&nbsp;12, 2025 (and which is available at https://www.sec.gov/ix?doc=/Archives/edgar/data/0001802768/000180276825000010/rprx-20241231.htm), and in the sections entitled &#147;Certain Relationships and Related Party Transactions,&#148; and
&#147;Security Ownership of Certain Beneficial Owners,&#148; included in the Company&#146;s definitive proxy statement in connection with its 2024 Annual General Meeting of Shareholders, as filed with the SEC on April&nbsp;25, 2024 (and which is
available at https://www.sec.gov/ix?doc=/Archives/edgar/data/1802768/000114036124022029/ny20020881x1_def14a.htm). Additional information regarding the interests of such participants in the solicitation of proxies in respect of the Transaction will
be included in the proxy statement and other relevant materials to be filed with the SEC when they become available. These documents can be obtained free of charge from the SEC&#146;s website at www.sec.gov. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Offer or Solicitation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication is not
intended to and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities or the solicitation of any vote of approval, nor shall there be any sale of securities in any
jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the
requirements of Section&nbsp;10 of the Securities Act of 1933, as amended. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>ROYALTY PHARMA PLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date: April&nbsp;10, 2025</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Pablo Legorreta</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Pablo Legorreta</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">


<IMG SRC="g943352g69k37.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right"><B>PRESS RELEASE</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ROYALTY PHARMA APPOINTS VLAD CORIC, M.D. TO THE COMPANY&#146;S BOARD OF DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NEW YORK, NY, April</B><B></B><B>&nbsp;8, 2025 &#150;</B> Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Vlad Coric, M.D. to the
company&#146;s Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer of Biohaven, a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key
therapeutic areas including neuroscience, immunology and oncology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I am excited to announce that we are strengthening our Board with the
appointment of Vlad Coric,&#148; said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma. &#147;Vlad&#146;s entrepreneurial approach and outstanding leadership skills, honed over a distinguished career in biopharma, will serve as
tremendous assets to Royalty Pharma. In addition, Vlad brings notable experience in the royalty funding space, having completed multiple transactions with us during his tenure at Biohaven. We look forward to leveraging his scientific expertise and
insights to advance our position as the leading partner funding innovation in life sciences.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Coric successfully led Biohaven through the
FDA approval and launch of Nurtec ODT for the treatment of migraine. Under his leadership, the company also filed an NDA for its second drug candidate, zavegepant, as the first intranasal CGRP antagonist for ultra-rapid relief of migraine. During
his tenure, Dr.&nbsp;Coric oversaw Biohaven&#146;s impressive growth from its founding through its sale to Pfizer in May of 2022 for approximately $13&nbsp;billion in total consideration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Coric has more than 20 years of drug discovery and clinical development experience at Yale School of Medicine and Bristol-Myers Squibb prior to
leading Biohaven. Within the pharmaceutical industry, Dr.&nbsp;Coric has expertise working across therapeutic areas including neurology, psychiatry, immunology, virology, oncology and immuno-oncology. During his career, he has been involved in
multiple drug development programs. Dr.&nbsp;Coric completed his postdoctoral internship, residency and fellowship at Yale School of Medicine, earned his medical degree from Wake Forest University School of Medicine and was an honors scholar in
neurobiology and physiology at the University of Connecticut, where he received his Bachelor of Science degree. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Royalty Pharma </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry,
collaborating with innovators from academic institutions, research hospitals and <FONT STYLE="white-space:nowrap">non-profits</FONT> through small and <FONT STYLE="white-space:nowrap">mid-cap</FONT> biotechnology companies to leading global
pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the <FONT STYLE="white-space:nowrap">top-line</FONT> sales of many of the industry&#146;s leading therapies. Royalty
Pharma funds innovation in the biopharmaceutical industry both directly and indirectly &#150; directly when it partners with companies to <FONT STYLE="white-space:nowrap">co-fund</FONT> late-stage clinical trials and new product launches in exchange
for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma&#146;s current portfolio includes royalties on more than 35 commercial products, including Vertex&#146;s Trikafta, GSK&#146;s
Trelegy, Roche&#146;s Evrysdi, Johnson&nbsp;&amp; Johnson&#146;s Tremfya, Biogen&#146;s Tysabri and Spinraza, AbbVie and Johnson&nbsp;&amp; Johnson&#146;s Imbruvica, Astellas and Pfizer&#146;s Xtandi, Novartis&#146; Promacta, Pfizer&#146;s Nurtec
ODT and Gilead&#146;s Trodelvy, and 15 development-stage product candidates. For more information, visit <U>www.royaltypharma.com</U>.&#8195; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Royalty
Pharma Investor Relations and Communications </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (212) <FONT STYLE="white-space:nowrap">883-6637</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>ir@royaltypharma.com </U></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g943352g69k37.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g943352g69k37.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MBB7)+<W000"#D5F4% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M'S3X^DLX?CU)+J(0V*7=HUP)%W+Y82+=D=QC/%>I1O[#3?4YI?'J>D_\)#\'
MO^>&A_\ @M'_ ,17+R8CS^\TO \H^*E_X4O]9LF\*1VJ0I"1-]FM_*0MGCC
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M9F<;<]\!1TX[#@5LYQE1ER[(E)J2N>^>(-<L_#>A76K7S8AMTSM'5V[*/<G
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MT5O"#D)$@10?H*3;>X]B:D 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M,EBCGA>&6-9(G4JR,,A@>H([BC8"GIVAZ3I#2-IFEV=D9  YMX%CW8Z9V@9J
MG*4MV))+8OU(PH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * (OM,'_ #VC_P"^A0 ?:8/^>T?_ 'T* #[3!_SVC_[Z% !]I@_Y[1_]
M]"@!?/B_YZI_WT* #SXO^>J?]]"@ \^+_GJG_?0H //B_P">J?\ ?0H //B_
MYZI_WT* #SXO^>J?]]"@ \^+_GJG_?0H //B_P">J?\ ?0H //B_YZI_WT*
M'>;'_?7\Z #S(_[Z_G0 >9'_ 'U_.@ \R/\ OK^= !YD?]]?SH /,C_OK^=
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M- !_9]K_ ,\O_'C0 ?V?:_\ /+_QXT ']GVO_/+_ ,>- !_9]K_SR_\ 'C0
M?V?:_P#/+_QXT ']GVPZ(1]&- !]@M_1O^^C0 ?8+?T;_OHT 'V"W]&_[Z-
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@E_>?WFS!%Y%O'"'9Q&H7<YRQP.I/K7+)W;9JE96/_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
